Accuray (NASDAQ:ARAY) Stock Crosses Above 200 Day Moving Average – What’s Next?

Shares of Accuray Incorporated (NASDAQ:ARAY) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.51 and traded as high as $1.75. Accuray shares last traded at $1.69, with a volume of 464,785 shares.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. BTIG Research boosted their price target on Accuray from $4.00 to $5.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Accuray in a research note on Saturday, September 27th. Finally, Wall Street Zen upgraded shares of Accuray from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.00.

Accuray Trading Up 2.4%

The company has a market cap of $190.50 million, a P/E ratio of -84.50 and a beta of 1.31. The company has a current ratio of 1.65, a quick ratio of 0.92 and a debt-to-equity ratio of 1.53. The business has a 50 day moving average price of $1.53 and a 200-day moving average price of $1.51.

Accuray (NASDAQ:ARAY) last issued its earnings results on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Accuray had a negative return on equity of 4.92% and a negative net margin of 0.35%.The firm had revenue of $127.54 million for the quarter, compared to analyst estimates of $123.78 million. Accuray has set its FY 2026 guidance at EPS. Analysts forecast that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Accuray

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Heartland Advisors Inc. raised its stake in Accuray by 11.8% in the first quarter. Heartland Advisors Inc. now owns 4,274,750 shares of the medical equipment provider’s stock valued at $7,652,000 after buying an additional 450,000 shares during the period. Armistice Capital LLC increased its holdings in shares of Accuray by 27.6% during the 2nd quarter. Armistice Capital LLC now owns 3,236,000 shares of the medical equipment provider’s stock worth $4,433,000 after acquiring an additional 700,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Accuray by 7.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,421,724 shares of the medical equipment provider’s stock worth $3,318,000 after acquiring an additional 174,703 shares during the last quarter. TENOR CAPITAL MANAGEMENT Co. L.P. bought a new stake in Accuray in the 2nd quarter valued at $2,055,000. Finally, Acuitas Investments LLC lifted its holdings in Accuray by 100.4% during the 1st quarter. Acuitas Investments LLC now owns 1,420,207 shares of the medical equipment provider’s stock valued at $2,542,000 after purchasing an additional 711,654 shares during the last quarter. Institutional investors own 64.08% of the company’s stock.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.